Dr. Siming Li is a senior expert in melanoma and genitourinary malignancies in China, with long-term dedication to the comprehensive management and research of melanoma, renal cell carcinoma, urothelial carcinoma, and related cancers. He previously conducted visiting studies at Massachusetts General Hospital (MGH), gaining a solid international academic foundation and advanced clinical insight.
Dr. Li has extensive experience in systemic treatments including chemotherapy, targeted therapy, and immunotherapy for melanoma and genitourinary cancers. He holds unique expertise in isolated limb infusion (ILI) for localized melanoma, targeted–immunotherapy combination strategies for mucosal melanoma, and targeted therapy for renal cell carcinoma. He has led and participated in multiple national key research projects and has served as a Sub-investigator in a range of phase I–III clinical trials involving novel targeted and immunotherapeutic agents for melanoma and genitourinary tumors. His research findings have been presented at major national and international academic conferences, contributing significantly to clinical advancement in these fields.
